Sentences with phrase «therapeutic model for»

As a certified Emotionally Focused Therapist and Supervisor using the most empirically validated and cutting edge therapeutic model for treating couples with the highest rate of success (75 % recovery rate or better) compared to all other models of couple treatment (35 % or less recovery rate), I can help you and your partner find security and connection in your relationship.

It is the ideal therapeutic model for children dealing with divorce, death, anxiety, trauma, anger, difficult life transitions, and other situations that cause stress or emotional pain.

«I utilize a strength - based therapeutic model for clients seeking support no matter the age, whether it's children, adolescents, adults, families, or groups.

Analyze a variety of therapeutic models for helping couples learn to transition into forgiveness and rebuild trust.

Not exact matches

Restoration Therapy is a Marriage and Family Therapeutic Model that efficiently identifies a client's identity and safety patterns, while empowering client emotional regulation and mindfulness for behavioral change.

Further studies in animal models and patients (with altered TRPM7 channel function) have been initiated, in order to evaluate the efficacy and safety of magnesium as a therapeutic for this disease.

For now, Rashid's group has a list of candidate therapeutic drugs that they'll test in their new liver disease models, something that may still prove useful to patients.

«We know that 70 - 75 percent of glioblastoma patients undergo surgery for tumor debulking, and we have previously shown that MSCs encapsulated in biocompatible gels can be used as therapeutic agents in a mouse model that mimics this debulking,» he continued.

«New model for hepatitis B helps identify potential new therapeutic approach.»

Instead of systematically testing the effects of known compounds — the pharmaceutical industry's basic model for more than a century — scientists can now investigate backward, combing through genomic data to find links between specific genotypes and diseases and then screening drug data to identify therapeutic candidates.

Because the researchers found that CTLA4Ig was effective in suppressing hepatitis in this study, they suggest that CTLA4Ig should be among the therapeutic options investigated further as a potential therapy for patients with severe acute hepatitis B. To this end, this animal model is useful for virological and immunological analysis of HBV infection.

This new technology offers two main advantages based on the use of molecular tools to manipulate the genome: firstly, working models that had not existed up until now for the study of tumour biology and, secondly, their application will eventually allow for the study of new therapeutic targets and therapies.

«And while the tumor model we're now studying doesn't present targets for new drugs, if we can discover the mechanism controlling that model, it may yield therapeutic drug targets.»

«Our work and that of our colleagues on stress and CRF have been mechanistically implicated in Alzheimer's disease, but agents that impact CRF signaling have not been carefully tested for therapeutic efficacy or long - term safety in animal models,» said the study's principal investigator and corresponding author Robert Rissman, PhD, assistant professor in the Department of Neurosciences and Biomarker Core Director for the Alzheimer's Disease Cooperative Study (ADCS).

Recently, Dr. Cohen's laboratory obtained an ethical approval to test the therapeutic efficiency of NT219 as a treatment in Alzheimer's - model mice, hoping to develop a future treatment for hitherto incurable neurodegenerative disorders.

«Network model of the musculoskeletal system predicts compensatory injuries: The authors» simplified musculoskeletal model could lead to clinical developments for testing therapeutic responses to injury.»

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

Dr. Zhu said he believes the study provides the scientific community with an important animal model to further investigate ARID1B's role in human brain disorders and will be a useful tool for therapeutic testing of potential treatments for autism, intellectual disability, and Coffin - Siris syndrome.

«The induced pluripotent stem cells we used in this study proved to be extremely useful in disease modelling, and they could offer an excellent platform for drug discovery and testing new therapeutic targets for Alzheimer's disease in the future,» says Early Stage Researcher Minna Oksanen, the lead author of the study.

«Novel imaging model helps reveal new therapeutic target for pancreatic cancer: Antisense treatment in preclinical models shows effectiveness against deadly tumors.»

Knowing that Notch governs vessel permeability makes it a candidate for new drugs to treat cardiovascular diseases as well, and the team is also investigating the TMD as a potential therapeutic agent itself, as cell models that were exposed to leak - inducing inflammation displayed a dramatic reduction in leakage when they were engineered to express the TMD.

The study of these new mouse models means an advance in the knowledge of disease's development mechanisms and an opportunity to implement new therapeutic strategies for patients.

Research teams are also developing ways to innovate the early drug - discovery process, including pioneering methods to rapidly identify drug targets and test them on laboratory models and finding and testing new therapeutic possibilities for already FDA - approved drugs.

This model, he said, could have important implications for the therapeutic use of stem cells to rejuvenate damaged tissues.

The Ospedale San Raffaele Mouse Clinic (OMC) is the follow - up and consolidation of a Regione Lombardia - funded project (EMDM), which aimed at the establishment and implementation of a large, dedicated facility (the European Mouse Disease Models Center) whose goal is the development and functional assessment of mouse disease models, both for the dissection of the underlying pathogenic mechanisms and for the screening and validation of innovative diagnostic and therapeutic proceModels Center) whose goal is the development and functional assessment of mouse disease models, both for the dissection of the underlying pathogenic mechanisms and for the screening and validation of innovative diagnostic and therapeutic procemodels, both for the dissection of the underlying pathogenic mechanisms and for the screening and validation of innovative diagnostic and therapeutic procedures.

The resulting data are being combined in a systems biology approach with high - resolution clinical phenotyping and findings obtained with a large array of established and novel in vitro, ex vivo and in vivo disease models to identify disease - associated genetic variants, disease - defining molecular signatures, and potential targets for therapeutic intervention.

This call for projects «Mouse models and rare diseases» aims to give a significant boost to the development of mouse models, in order to: ◊ gain a better understanding of the pathophysiological mechanisms involved in rare diseases whose defective genes have been identified ◊ test and validate therapeutic proofs of concept, at the pre-clinical in vivo level Indeed, producing these models meets a key objective in the development of a therapeutic strategy.

The researchers are now testing the efficacy of the technique in animal models to verify its potential for therapeutic use.

These models would be ideal platforms for identifying new genetic treatments and validating potential therapeutic options.

Validating this concept, we previously demonstrated that human pluripotent stem cells and derivatives which, express the causal mutation implicated in the Myotonic Dystrophy type 1 (DM1), offer pertinent disease - cell models, applicable for a wide systemic analysis ranging from mechanistic studies to therapeutic screening.

This work provided greater mechanistic understanding of airway remodeling that occurs as a result of viral exacerbation in respiratory diseases and an improved model for predicting the response to therapeutic candidates.

With the reference cell census data in hand, the research team is excited to conduct additional studies, including ones involving models or human patients with gastrointestinal conditions — Crohn's disease, ulcerative colitis, gastrointestinal cancers, forms of food allergy, etc. — aimed at identifying changes in gene expression and epithelial structure and function that could reveal new insights and opportunities for therapeutic development.

Objective: To provide data - driven and computational infrastructures and data - sharing platforms to support large - scale, system - level data integration and modeling, and enable predictive biology for pathogens and host - pathogen interactions for discovery research, clinical investigation, and therapeutic development for infectious diseases.

PHENOMIN - ICS offers to generate genetically modified mouse models on a high - throughput and large scale basis, and then to provide a first phenotyping characterisation, either standardised or more specific, for a better understanding of disease mechanisms and for the development of new therapeutic treatments.

In her translational research program, Dr. Duff has created several transgenic mouse models for Alzheimer's disease (AD) to explore disease mechanisms and test therapeutic approaches.

This earlier period of disease identification presents a valuable model for early intervention and improved assessment of potential therapeutic approaches for ALS.

Importantly, the molecular imaging models that are developed can be employed to accelerate the discovery of targets and drugs for therapeutic intervention, and biomarkers that could be used for early diagnosis.

This molecule brings a revolutionary technology platform for genetic engineering in vertebrates, including gene discovery in model species and for therapeutic transgene delivery for possible human applications.

The comprehensive information presented for each cell therapy includes: an overview of the therapy, a list of therapeutic cells utilized in the specific treatment, mode and regimen of cell delivery, mechanism of action, formulation, in vitro data, animal models, preclinical data and related clinical trials.

A ferrocentric model of AD described here forms the basis of a rational, easily testable experimental therapeutic approach for AD, which if successful, would be both widely applicable and inexpensive.

The phenotyping platforms of PHENOMIN - ICS area, adapted to study genetically modified mouse models, can also be used for preclinical studies, including the validation of therapeutic targets, as well as pharmaceutical and toxicological studies in mice.

Because of the ease with which the CRISPR / Cas9 system can be applied, it has quickly become a robust tool for generating accurate genetic disease models in the laboratory and for identifying novel therapeutic targets in the clinic.

Using genetic and epigenetic analyses coupled with powerful perturbation technologies to test gene functions in human cells and mouse models, we hope to identify the critical drivers of this disease and the basis for therapeutic responses.

Collagen Antibody Induced Arthritis (CAIA) is a simple mouse model of rheumatoid arthritis that can be used for the fast preclinical efficacy evaluation of candidate therapeutic agents targeting pathogenic mechanisms and inflammatory processes of arthritis.

The Tg5453 mouse model was successfully used in establishing the therapeutic efficacy of Remicade ®, the first anti-TNF therapeutic to be successfully applied in the clinic, and is recommended by the FDA for screening potential anti-rheumatoid candidate drugs.

The lab recently developed novel LumiFluor ® optical reporters and are now implementing these reporters for the non-invasive, high resolution in vivo optical imaging of tumor development, progression, and response to therapeutic intervention in genetically engineered mouse models (GEMM) of cancer.

Such models will allow for further understanding of critical genes and microRNAs involved in sarcoma development, progression and metastasis and can be utilized as preclinical models for therapeutic testing and efficacy.

Her work focuses on using RNA vaccines for Leishmaniasis and prostate cancer to generate protective or therapeutic immune responses in mouse models and evaluate in an artificial lymph node system.

We now have an excellent model for this childhood disorder to learn about the molecular causes of disease and to test for potential therapeutic strategies.

Studies using a mouse model of type 1 diabetes highlight a potential role for human adipose stem cells in treatment regimens and, further, they reveal a secreted factor which has important therapeutic relevance